Roivant Sciences Ltd.
ROIV
71 insider filings · Latest: Oct 1, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Jun 29 8:40 PM | MELISSA EPPERLY | Proposed Sale | 17,750 | $34.07 | $604.7K | — | View → |
| Jun 24, 2026 | Jun 26 10:13 PM | Eric VenkerPresident & Immunovant CEO | Sale | 200,000 | $33.16 | $6.6M | 1,613,063(D) | View → |
| Jun 26, 2026 | Jun 26 8:10 PM | MAYUKH SUKHATME | Proposed Sale | 500,000 | $34.08 | $17.0M | — | View → |
| Jun 25, 2026 | Jun 25 8:33 PM | MAYUKH SUKHATME | Proposed Sale | 500,000 | $34.13 | $17.1M | — | View → |
| Jun 24, 2026 | Jun 24 8:01 PM | Venker Eric | Proposed Sale | 200,000 | $33.16 | $6.6M | — | View → |
| May 22, 2026 | May 22 10:25 PM | Eric VenkerPresident & Immunovant CEO | Sale | 200,000 | $30.27 | $6.1M | 1,613,063(D) | View → |
| May 22, 2026 | May 22 8:00 PM | Venker Eric | Proposed Sale | 200,000 | $30.27 | $6.1M | — | View → |
| Apr 20, 2026 | Apr 22 10:27 PM | Eric VenkerPresident & Immunovant CEO | Sale | 200,000 | $29.59 | $5.9M | 1,647,546(D) | View → |
| Apr 16, 2026 | Apr 20 10:27 PM | Matthew GlineDirector, CEO | Sale | 289,774 | $29.16 | $8.4M | 16,736,116(D) | View → |
| Apr 20, 2026 | Apr 20 8:17 PM | Venker Eric | Proposed Sale | 200,000 | $29.59 | $5.9M | — | View → |
| Apr 16, 2026 | Apr 16 9:24 PM | Gline Matthew | Proposed Sale | 289,774 | $29.16 | $8.4M | — | View → |
| Apr 16, 2026 | Apr 16 8:33 PM | Gline Matthew | Proposed Sale | 289,774 | $29.16 | $8.4M | — | View → |
| Apr 8, 2026 | Apr 10 10:00 PM | Jennifer HumesChief Accounting Officer | Sale | 13,538 | $28.37 | $384.1K | 84,191(D) | View → |
| Apr 8, 2026 | Apr 8 8:07 PM | JENNIFER HUMES | Proposed Sale | 13,538 | $28.37 | $384.0K | — | View → |
| Mar 26, 2026 | Mar 31 1:01 AM | Meghan FitzgeraldDirector | Sale | 70,000 | $27.45 | $1.9M | 42,963(D) | View → |
| Mar 26, 2026 | Mar 26 8:14 PM | MEGHAN FITZGERALD | Proposed Sale | 70,000 | $27.45 | $1.9M | — | View → |
| Mar 17, 2026 | Mar 19 10:36 PM | Eric VenkerPresident & Immunovant CEO | Sale | 200,000 | $28.24 | $5.6M | 1,647,546(D) | View → |
| Mar 16, 2026 | Mar 18 10:23 PM | Melissa B, EpperlyDirector | Sale | 41,861 | $28.68 | $1.2M | 15,804(D) | View → |
| Mar 17, 2026 | Mar 17 8:17 PM | Venker Eric | Proposed Sale | 200,000 | $28.24 | $5.6M | — | View → |
| Mar 16, 2026 | Mar 16 8:04 PM | MELISSA B EPPERLY | Proposed Sale | 41,861 | $28.68 | $1.2M | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Oct 5 10:05 PM | Melissa B, EpperlyDirector | Option Exercise | 17,750 | $4.46 | 151,416(D) | View → |
| Sep 30, 2026 | Oct 2 9:37 PM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 3,644,834(D) | View → |
| Sep 16, 2026 | Sep 19 1:00 AM | Keith S ManchesterDirector | Grant/Award | 10,531 | $39.57 | 10,531(D) | View → |
| Sep 16, 2026 | Sep 18 11:12 PM | Daniel Allen GoldDirector | Grant/Award | 10,531 | $39.57 | 10,531(D) | View → |
| Sep 16, 2026 | Sep 18 11:06 PM | Ilan OrenDirector | Grant/Award | 10,531 | $39.57 | 10,531(D) | View → |
| Sep 16, 2026 | Sep 18 11:01 PM | James C MomtazeeDirector | Grant/Award | 10,531 | $39.57 | 10,531(D) | View → |
| Sep 16, 2026 | Sep 18 10:57 PM | Meghan FitzgeraldDirector | Grant/Award | 10,531 | $39.57 | 10,531(D) | View → |
| Sep 16, 2026 | Sep 18 10:56 PM | Melissa B, EpperlyDirector | Grant/Award | 10,531 | $39.57 | 10,531(D) | View → |
| Sep 8, 2026 | Sep 11 1:00 AM | Meghan FitzgeraldDirector | Option Exercise | 20,000 | $8.80 | 18,578(D) | View → |
| Aug 28, 2026 | Sep 2 1:00 AM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 3,844,834(D) | View → |
| Aug 21, 2026 | Aug 22 1:00 AM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 144,756 | $3.85 | 13,224,363(D) | View → |
| Aug 20, 2026 | Aug 22 1:00 AM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 17,519 | $3.85 | 13,369,119(D) | View → |
| Aug 19, 2026 | Aug 22 1:00 AM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 172,899 | $3.85 | 13,386,638(D) | View → |
| Aug 18, 2026 | Aug 19 1:00 AM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 136,942 | $3.85 | 13,559,537(D) | View → |
| Aug 17, 2026 | Aug 19 1:00 AM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 284,707 | $3.85 | 13,696,479(D) | View → |
| Aug 14, 2026 | Aug 19 1:00 AM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 243,177 | $3.85 | 13,981,186(D) | View → |
| Jul 27, 2026 | Jul 30 1:00 AM | Eric VenkerPresident & Immunovant CEO | Option Exercise | 200,000 | $3.85 | 4,044,834(D) | View → |
| Jun 30, 2026 | Jul 2 11:03 PM | Meghan FitzgeraldDirector | Option Exercise | 10,000 | $8.80 | 38,578(D) | View → |
| Jun 29, 2026 | Jul 1 10:34 PM | Melissa B, EpperlyDirector | Option Exercise | 17,750 | $4.46 | 169,166(D) | View → |
| Jun 26, 2026 | Jun 29 10:23 PM | Mayukh SukhatmeDirector, President & CIO | Option Exercise | 500,000 | $3.85 | 14,224,363(D) | View → |
Page 1 of 2
Next →